Published on
July 9, 2024
- 13:00 GMT
Contraline's First In-Human Trial Shows Safety with 12-Month Efficacy Signals of the ADAM™ Male Contraceptive Device
CHARLOTTESVILLE, VA, UNITED STATES, July 9, 2024 /EINPresswire.com/ -- Contraline, a clinical-stage biotechnology company, has announced promising initial safety and efficacy results from its First-in-Human clinical trial. The trial, which is evaluating …
Distribution channels:
Healthcare & Pharmaceuticals Industry
...
